

PROSPECTS

IN PHARMACEUTICAL SCIENCES

Prospects in Pharmaceutical Sciences, 24(1), 39-45
<https://prospects.wum.edu.pl/>

Original Article

SOLUBILITY ENHANCEMENT OF DIACEREIN THROUGH LIQUISOLID TECHNOLOGY: A FORMULATION PERSPECTIVE

Monika Nijhawan*¹, Rajeswari Aleti¹, Sravani Maramwar¹, Dedipya Goda Srivalli Vangala¹, Trapti Saxena²

¹ Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana 500090, India.

² Department of Pharmaceutics, G. Pulla Reddy College of Pharmacy, Hyderabad, Telangana 500028, India.

* Correspondence, e-mail: monika8009@grcp.ac.in

Received: 21.04.2025 / Revised: 04.08.2025 / Accepted: 15.08.2025 / Published online: 01.10.2025 /
Published in final version: 29.01.2026

ABSTRACT

Liquisolid systems present an effective technique for improving the dissolution rate and oral bioavailability of poorly water-soluble drugs. The objective of this study is to formulate and evaluate diacerein liquisolid compacts using Tween 80 as the liquid vehicle, Neusilin and Fujicalin as carriers, and Aerosil 200 as a coating material. Sodium starch glycolate and magnesium stearate were used as disintegrants and lubricants, respectively. Pre- and post-compression parameters such as flow properties, hardness, friability, drug content, and disintegration time were measured. The in vitro release characteristics of the pure drug, marketed capsules (as reference), and liquisolid technique (test sample) were studied. Among all the formulations, FSC3 had the highest dissolving efficiency (DE) of 53.109% at 60 minutes, exceeding the marketed product's DE of 44.972%. FTIR analysis revealed no drug-excipient incompatibility, and all tested formulations fulfilled pharmacopeial requirements for flow and mechanical characteristics. Overall, the study demonstrates that the liquisolid technique significantly improves the dissolution of diacerein, indicating its potential to boost the physicochemical properties of poorly soluble drugs.

KEYWORDS: liquisolid compacts, diacerein, solubility enhancement, poorly aqueous-soluble, formulation development.

Article is published under the CC BY license.

1. Introduction

Solubility plays a critical role in drug bioavailability, particularly in oral formulations. However, approximately 70% of new drug candidates and 40% of marketed immediate-release oral drugs suffer from low aqueous solubility, leading to poor absorption and inconsistent therapeutic effects. This presents a major challenge for the pharmaceutical industry in developing effective formulations with enhanced dissolution and bioavailability [1,2].

Diacerein, a BCS Class II drug and a chondroprotective agent, is administered orally at a dose of 50 mg per day. Its absolute oral bioavailability ranges from 35% to 56% [3]. Several strategies have been explored to improve its solubility, including micronization, nanonization, cyclodextrin complexation, and solid dispersions. While liquid dosage forms can enhance solubility, they are prone to stability issues and incompatibilities. In contrast, solid dosage forms such as tablets offer advantages like better stability, ease of handling, longer shelf life, and cost-effective large-scale production [4,5].

Liquisolid technology is an innovative approach that transforms liquid drugs, suspensions, or drug solutions into free-flowing, compressible powders using porous carriers such as microcrystalline cellulose and coating agents like colloidal silica. Non-volatile liquid vehicles, such as propylene glycol, polyethylene glycols, and glycerine, play a crucial role in this conversion. By increasing the surface area, solubility, and wettability of drug particles, liquisolid systems significantly enhance drug dissolution, leading to better gastrointestinal absorption and improved bioavailability. Additionally, they help overcome challenges like poor wettability, variable dissolution rates, and erratic drug release seen in conventional formulations [6,7].

2. Materials and Methods

Diacerein was purchased from Chorus Labs Pvt Ltd., Karnataka. PEG 300, PEG 400, Tween 20, Tween 80, Brij 35, Kolliphor RH40, magnesium stearate, and sodium starch glycolate were procured from S.D. Fine-Chem. Ltd., Mumbai. Neusilin, Aerosil 200, and Fujicalin were sourced from Aurobindo Pharma Ltd., Hyderabad. All the chemicals

and reagents were of analytical grade and were used as obtained.

2.1. Solubility determination in non-volatile solvents

Diacerein solubility was assessed in PEG 300, PEG 400, Tween 80, Tween 20, Brij 35, Kolliphor RH40, and water to select the optimal solvent. Excess drug was added to each solvent and shaken in an orbital shaker at 25 °C for 48 hours. The saturated solutions were then filtered through Whatman filter paper, and the filtrate was analyzed using UV spectrophotometry at 343 nm [8].

2.2. Angle of slide (θ) determination

The angle of slide assessed the flow properties and flowable liquid-retention potential (ϕ) of Neusilin and Fujicalin with Tween 80. Admixtures of 10 g Neusilin and 5 g Fujicalin with varying liquid-vehicle concentrations (0.2–2.0 w/w) were placed on a polished tile and tilted until the powder began to slide, defining the angle of slide [9].

2.3. Load factor calculation

Drug-loaded liquid medication was blended with a carrier-coating admixture, and the loading factor (Lf) was determined using $Lf = W/Q$, where W is the liquid medication weight and Q is the carrier concentration. Neusilin (10 g) or Fujicalin (5 g) was mixed with the liquid vehicle for 10 minutes, and the calculated Lf value guided the required carrier and coating material amounts [10,11].

2.4. Compressible liquid retention potential (Ψ) determination

Various liquid-carrier admixtures with different liquid-solid weight ratios were prepared, similar to the angle of slide method. Each admixture was compressed into a tablet to assess maximum hardness, observing for liquid squeeze-out. The Ψ -value was defined as the highest liquid-to-carrier ratio before liquid squeeze-out occurred [12].

2.5. Preparation of liquisolid compacts

Diacerein liquisolid compacts were prepared using Neusilin and Fujicalin as carriers, Tween 80 as the liquid vehicle, and drug concentrations of 5%, 10%, and 15% w/w. (Tables 1 and 2). The drug and non-volatile solvent were accurately weighed, blended until fully dissolved, and then mixed with carrier and coating materials. The three-stage mixing process involved (1) initial blending for uniform distribution, (2) a five-minute absorption phase for drug penetration, and (3) final blending with sodium starch glycolate. The carriers transformed the wet mixture into a free-flowing dry powder with optimal compression properties. Sodium starch glycolate, magnesium stearate, and Aerosil 200 (R=20) were incorporated as a disintegrant, lubricant, and coating agent, respectively. The final blend was evaluated for flowability and compressed into tablets using a multi-rotary press with 12-mm biconvex punches to ensure appropriate tablet hardness [13,14].

Table 1. Formulation composition NSC 1–NSC 3 with Neusilin as carrier material.

S.no	Ingredients	Quantity (mg/tab)		
		NSC 1	NSC 2	NSC 3
	Drug conc. in Tween 80 (%w/w)	5%	10%	15%
1	Diacerein(mg)	50	50	50
2	Tween 80 (mg)	95	449	283
3	Neusilin (mg)	104	350	237
4	Aerosil 200 (mg)	5	20	14
5	SSG (mg)	30	30	30
6	Magnesium stearate (mg)	1	1	1
	Unit dose weight (mg)	285	900	615

Table 2. Formulation composition FSC 1–FSC 3 with Fujicalin as carrier material.

Sno	Ingredients	Quantity (mg/tab)		
		FSC 1	FSC 2	FSC 3
	Drug conc. in Tween 80 (%w/w)	5%	10%	15%
1	Diacerein(mg)	50	50	50
2	Tween 80 (mg)	940	450	283
3	Fujicalin (mg)	237	158	555
4	Aerosil 200 (mg)	12	11	26
5	SSG (mg)	30	30	30
6	Magnesium stearate (mg)	1	1	1
	Unit dose weight (mg)	1270	700	945

2.6. Precompression studies

Flow properties were measured in triplicate for diacerein and liquisolid compact tablets using standard pharmacopoeial methods [15].

2.6.1. Angle of repose

The angle of repose is the maximum angle between a powder heap and the horizontal, indicating powder flow properties. It was determined by pouring powder from a 2 cm height and calculating the angle using the formula $\theta = \tan^{-1}(h/r)$, where h is the height and r is the average radius.

2.6.2. Carr's Index (% CI)

Carr's index measures flow properties and packing ability. It is calculated using bulk (Db) and tapped density (Dt) as: $CI (\%) = (Dt - Db)/Dt \times 100$.

2.6.3. Hausner's Ratio

Hausner's ratio assesses flowability and packing efficiency, with values close to 1 indicating good flow and packing properties. It is calculated as:

$$\text{Hausner's ratio} = Dt/Db$$

where Dt is tapped density and Db is bulk density.

2.7. Evaluation of compressed tablets

2.7.1. Post-compression studies

2.7.1.1. Physical appearance

The general appearance of a tablet, including its size, shape, color, odor, and taste, is crucial for consumer acceptance and ensuring uniformity between batches [16].

2.7.1.2. Size and shape

Tablet dimensions are controlled, with thickness as the only variable, measured using a micrometer and maintained within $\pm 5\%$ of the standard value [17].

2.7.1.3. Weight variation

As per United States Pharmacopeia (USP) guidelines, 20 tablets were weighed individually and compared to the average weight. The batch met the requirements if not more than two tablets deviated beyond the specified limit, and none exceeded twice that limit [18].

2.7.1.4. Hardness

Five tablets from each batch were selected, and hardness was measured using a hardness tester to find the average tablet hardness or crushing strength [18].

2.7.1.5. Friability

Friability was determined by taking six tablets. Tablet samples were weighed accurately and placed in a Roche friabilator and operated for the given specification (4 min at 25 rpm) [18].

2.7.1.6. Drug content

Ten tablets from each formulation were powdered. The powdered sample equivalent to 100 mg of drug was transferred to a 100 mL volumetric flask containing 100 mL of 0.1 N hydrochloric acid solution. The contents were shaken for up to 30 min. The drug content was determined by measuring the absorbance at 343 nm [17].

2.7.1.7. Disintegration test

Six tablets were taken randomly from each batch and placed in a USP disintegration apparatus basket. The apparatus was run for 10 minutes, and the basket was lifted to observe whether all of the tablets had disintegrated [17].

2.7.1.8. In vitro drug release

In vitro drug release of the samples was carried out using a USP-type II dissolution apparatus (paddle type) at 100 rpm in 900 mL of 0.1 N HCl at $37 \pm 0.5^\circ\text{C}$. At different time intervals, 5 mL of the sample was withdrawn and filtered. The fresh dissolution medium was replaced every time with the same quantity of the sample. Collected samples were analyzed at 343 nm. The percentage cumulative drug release (% CDR) was calculated [17].

2.8. Comparison of dissolution profiles

To compare dissolution profiles between two drug products, model-dependent, statistical analysis, and model-independent methods can be used [19,20]. Dissolution profiles of formulations were compared on the basis of dissolution efficiency (DE) and mean dissolution time (MDT) with the marketed formulation.

2.9. FTIR - spectroscopy

The FT-IR studies were carried out to confirm the compatibility of diacerein with the excipients used in the formulation. The FT-IR scans for the pure drug and physical mixtures of drug and different excipients were recorded on an FTIR spectrophotometer (IR Sipirit - X, Shimadzu). The spectrum was recorded in the wavelength region of $4000\text{--}400\text{ cm}^{-1}$ as shown in Fig. 7. The characteristic absorption peaks were observed for the pure drug.

3. Results

3.1. Saturation solubility studies

The solubility of diacerein was evaluated in various non-volatile solvents (PEG 300, PEG 400, Tween 20, Tween 80, Kolliphor RH40, Brij 35, and water) at 25°C (Fig. 1). Tween 80 showed the highest solubility, making it ideal for liquisolid formulations, as higher solubility enhances drug dissolution in the liquid vehicle before adsorption onto carriers, improving drug release.




Fig. 1. Solubility of diacerein in various non-volatile solvents.

3.2. Determination of angle of slide (θ) of powder excipients (Neusilin and Fujicalin)

The optimum angle of the slide was considered to be 33° . For the Neusilin-Tween 80 admixture, the angle of slide was 33.5° at $\phi = 1.4$ (Fig. 2), while for Fujicalin, it was 32.9° at $\phi = 0.6$ (Fig. 3), ensuring acceptable flow. These values help determine the required carrier amount for a free-flowing, non-adherent, and readily compactable liquisolid formulation.




Fig. 2. Angle of slide of admixture of Neusilin and Tween 80.




Fig. 3. Angle of slide of admixture of Fujicalin and Tween 80.

3.3. Determination of compressible liquid-retention potential (Ψ value)

Compressible liquid-retention potential (Ψ value) was determined for the prepared admixtures. For Neusilin-Tween 80 admixtures, i.e., 0.2 to 2.0, and Fujicalin-Tween 80 admixtures 0.2 to 1.0, during tablet compression, the liquid squeezed out at 1.4 for Neusilin and 0.6 for Fujicalin. Therefore, the values prior to these were considered as the compressible liquid-retention potential. From the load factor with proper flow and compressible liquid-retention potential values, it can be concluded that Neusilin can retain liquid medication with proper flow without any liquid squeeze-out phenomenon in the ratio of 1.4, and in the case of Fujicalin it was found to be 0.6. For optimal flow properties ($\theta \approx 33^\circ$), the flowable liquid-retention potential (ϕ) was determined. The Neusilin-Tween 80 admixture had an angle of slide of 33.95° with a corresponding ϕ value of 1.4, while the Fujicalin-Tween 80 admixture had an angle of slide of 32.9° with a ϕ value of 0.6.

3.4. Flow properties of powder excipients

Tween 80/carrier admixtures with varying liquid-vehicle concentrations were prepared and evaluated for bulk and tapped density to determine Hausner's ratio and Carr's index (Tables 3 and 4), as per the described methods.

Table 3. Flow properties of Neusilin in Tween 80

ϕ values (w/w)	Bulk density (g/cc)	Tapped density (g/cc)	Hausner's ratio	Carr's index (%)
0.0	0.48±0.08	0.58±0.02	1.20	17.0
0.2	0.51±0.02	0.58±0.08	1.148	12.9
0.4	0.55±0.05	0.66±0.06	1.132	11.7
0.6	0.5±0.01	0.58±0.08	1.11	10
0.8	0.45±0.04	0.55±0.05	1.22	18.198
1.0	0.47±0.06	0.55±0.05	1.165	14.23
1.2	0.43±0.04	0.5±0.01	1.101	13.2
1.4	0.41±0.06	0.47±0.06	1.144 Good	12.6 Good
1.6	0.38±0.04	0.45±0.04	1.18	15.41
1.8	0.4±0.04	0.45±0.04	1.135	11.89
2.0	0.41±0.06	0.51±0.02	1.20	16.8

*Each value is an average of three determinations.

Table 4. Flow properties of Fujicalin in Tween 80.

ϕ values (w/w)	Bulk density (g/cc)	Tapped density (g/cc)	Hausner's ratio	Carr's index (%)
0.0	0.23±0.02	0.27±0.07	1.077	16.2
0.2	0.22±0.07	0.26±0.02	1.10	12.6
0.4	0.20±0.08	0.25±0.01	1.20	16.8
0.6	0.20±0.05	0.22±0.02	1.25 Fair	20 Fair
0.8	0.18±0.05	0.22±0.07	1.22	18.45
1.0	0.19±0.02	0.21±0.06	1.13	11.5

*Each value is an average of three determinations.

3.5. Formulation development

3.5.1. Pre-compression parameter of formulation blends of NSC 1–3 and FSC 1–3

Pre-compression parameters of NSC 1–3 and FSC 1–3 were evaluated to assess flow properties, with results shown in Table 5.

Table 5. Pre-compression parameter of formulation blend of NSC 1–3 and FSC 1–3

LSC	Hausner's ratio (%)	Carr's index (%)	Angle of repose (θ)
NSC 1	1.15	20	31.2±1.32
NSC 2	1.21	18.5	33.5±2.16
NSC 3	1.0	10	30.94±2.16
FSC 1	1.21	18	32.96±1.001
FSC 2	1.15	13.3	37.2±1.37
FSC 3	1.21	17.7	33.4±1.604

*Each value is an average of three determinations

The formulation blends exhibited passable to good flow, with Hausner's ratio ranging from good to moderate and Carr's index from fair to passable.

3.6. Evaluation of liquid solid tablets

Evaluation tests of formulation NSC 1–3, FSC 1–3 tablets were studied and reported in Table 5. All tablet batches met USP specifications, with percent deviation within limits (Table 6), ensuring uniformity. Formulations had a hardness of 3.3–5.3 kg/cm² (Table 6). NSC 2, 3 and FSC 2, 3 exhibited good mechanical strength, meeting the acceptable limit of ≥ 4.5 kg/cm². NSC 2, 3 and FSC 1, 2, 3 had friability <1%, meeting USP limits, indicating good mechanical resistance. NSC 1 exceeded 1%, making it non-compliant. Tablets disintegrated within 3–5 minutes, slightly higher for an immediate-release formulation. This delay may be due to sodium starch glycolate forming a viscous gel layer, hindering penetration of the disintegration medium. Drug content was consistently above 98%, ensuring uniform API distribution across all formulations.

Table 6. Post-compression evaluation tests of formulation NSC 1–3, FSC 1–3 tablets.

Formulations	Weight variation(mg)* (A.M± S.D)	Hardness (kg/cm ²)* (A.M±S.D)	Friability (%) (A.M±S.D)	Disintegration Time (min)* (A.M±S.D)	Drug content (%)* (A.M±S. D)
NSC 1	284.63±0.035	3.4±0.04	1.046±0.04	4.16±0.040	98.25±0.86
NSC 2	900±0.01	5.02±0.191	0.85±0.096	4.73±0.642	99.47±0.14
NSC 3	615±0.957	4.62±0.426	0.886±0.06	4.166±0.763	98.65±0.88
FSC 1	1270.50±0.02	3.322±0.237	0.763±0.066	3.76±0.251	99.61±0.12
FSC 2	700.152±0.00	5.344±0.263	0.93±0.051	3.46±0.533	98.45±0.54
FSC 3	945.656±0.01	4.46±0.160	0.923±0.066	5.13±0.320	99.18±0.12

3.7. In vitro dissolution studies

NSC 1–3 and FSC 1–3 formulations were subjected to in vitro dissolution studies in 0.1 N hydrochloric acid solution. The corresponding dissolution profile was presented, and the comparative in vitro dissolution profile was given in Figs. 4 – 6.




Fig. 4. In vitro drug release of the drug from tablets of batches NSC1–3, marketed and pure drug.




Fig. 5. In vitro drug release of the drug from tablets of batches FSC1–3, marketed and the pure drug.




Fig. 6. In vitro drug release of the drug from tablets of batch FSC 3 and marketed.

Figs. 4 and 5 illustrate the in vitro drug-release profile of the liquisolid formulations, pure drug and marketed formulation. All the liquisolid compacts showed higher drug release than the pure drug. The results showed that there was a significant difference between the release profile of the pure drug and the liquisolid compacts. The enhanced dissolution rates of liquisolid compacts compared to pure drug may be attributed to the fact that the drug is already in solution in Tween 80, while at the same time it is carried by the powder particles (Aerosil, Neusilin, or Fujicalin). Thus, its release is accelerated due to its markedly increased wettability and surface availability to the dissolution medium. The wettability of the compacts by the dissolution medium is one of the proposed mechanisms for explaining the enhanced dissolution rate from the liquisolid compacts. Tween 80 facilitates wetting of drug particles by decreasing interfacial tension between the medium and tablet surface. The formulations having high drug concentration in tween 80 showed rapid drug release. An increase in the concentration of drug in Tween 80 increases the dispersion of drug at the molecular level, which may further enhance the dissolution rate of the drug.

From the results of different batches prepared by two different carriers, it was found that Fujicalin proved to be the superior carrier compared to Neusilin. Further, diacerein liquisolid compacts' dissolution profile was compared with marketed capsules (Durajoint). FSC3 exhibited a drug-release profile similar to Durajoint capsules (Fig. 6).

DE is commonly applied for comparison of dissolution profiles to decide the better formulation. The marketed formulation showed 44.972%. The DE of the optimized liquisolid formulation FSC3 was found to be 53.109 % at the end of 60 min. Higher DE indicated that the liquisolid compact has significantly enhanced dissolution. MDT of the marketed formulation was found to be 43.8 min, while that of formulation FSC3 was 37.78 min. Lower MDT values indicated faster release of drug from the liquisolid formulation. Finally, on the basis of total drug release, tablet hardness, DE (%), and MDT, formulation FSC3 showed promising in vitro results.

3.8. FTIR Spectroscopy

IR spectrum of diacerein revealed an absorption band with peaks at 3068.7 cm⁻¹ (=C-H), 1764.86 cm⁻¹ (C=O (ester)), 1657.21 cm⁻¹ (C=O (COOH)), and 1256 cm⁻¹ (C-O). These peaks can be considered as characteristic peaks of diacerein and were not affected and were prominently observed in IR spectra of diacerein along with oil and carrier materials as shown in Fig. 7.




Fig. 7. Overlay IR of (A) drug (diacerein), (B) Neusilin, (C) Aerosil 200, (D) Fujicalin, (E) magnesium stearate, (F) sodium starch glycolate.

Characteristic peaks of the individual excipients were also retained; no new peak was found in the drug-loaded mixture of the excipients to be formulated in liquisolids. This indicates that there is no interaction between the drug and excipients.

4. Conclusions

The results suggest that liquisolid compacts of diacerein can be successfully prepared using novel carriers such as Neusilin and Fujicalin combined with non-volatile solvents like Tween 80. Both Fujicalin and Neusilin exhibited excellent potential for loading the non-volatile solvent while preserving favourable flow properties and enhancing dissolution compared to the pure drug and marketed formulation. Notably, formulation FSC3 demonstrated a lower mean dissolution time (MDT) and higher dissolution efficiency than the commercially available formulation. These findings highlight the promising potential of liquisolid technology to improve the therapeutic efficacy of poorly water-soluble drugs like diacerein.

Author Contributions: Concept, Design - M.N.; R.A.; Data Collection and/or Processing - S.M., D.V.; Literature Search -M.N., S.M., D.V.; Analysis and/or Interpretation - R.A., T.S., M.N., S.M.; Writing -T.S., S.M., D.V., M.N.; Critical Reviews - T.S., R.A., M.N. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: The authors express their gratitude to GRCP, Hyderabad, for their support in conducting the studies.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kumari, L.; Choudhari, Y.; Patel, P.; Gupta, G.D.; Singh, D.; Rosenholm, J.M.; Bansal, K.K.; Kurmi, B.D. Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs. *Life* **2023**, *13*(5), Art. No: 1099. DOI: 10.3390/life13051099
2. Kumar, H.; Rajpoot, A.K.; Sharma, S.; Kumar, A. Solid Lipid Nanoparticles: A Strategy to Improve Oral Delivery of the Biopharmaceutics Classification System (BCS) Class II Drugs. *Int. J. Pharm. Biol. Sci. Arch.* **2018**, *9*(4), 204-215.
3. Eltobshi, A.A.; Mohamed, E.A.; Abdelghani, G.M.; Nouh, A.T. Self-nanoemulsifying drug-delivery systems for potentiated anti-inflammatory activity of diacerein. *Int. J. Nanomed.* **2018**, *13*, 6585-6602. DOI: 10.2147/IJN.S178819
4. Premakumar, S.V.; B. A, Vishwanath.; Deepthi Swapna. Enhancement of Solubility and Dissolution Rate of BCS Class II Drugs. *Int. J. Pharm. Sci. Rev. Res.* **2024**, *84*(7), 153-161. DOI: 10.47583/ijpsrr.2024.v84i07.023
5. Talekar, S.; Dave, R. Solubility enhancement of a BCS class II drug using granulated fumed silica as an adsorbent. *J. Pharm. Res. Int.* **2017**, *18*(6), Art. No: JPRI.36872. DOI: 10.9734/JPRI/2017/36872
6. Kumar Nagabandi, V.; Ramarao, T.; Jayaveera, K.N. Liquisolid compacts: a novel approach to enhance bioavailability of poorly soluble drugs. *Int. J. Pharm. Biol. Sci.* **2011**, *1*(3), 89-102.
7. Dias, R.J.; Mali, K.K.; Ghorpade, V.S.; Havaladar, V.D.; Mohite, V.R. Formulation and evaluation of carbamazepine liquisolid compacts using novel carriers. *Indian. J. Pharm. Educ. Res.* **2017**, *51*(S2), S69-78. DOI: 10.5530/ijper.51.2s.52
8. Nijhawan, M.; Santhosh, A.; Babu, P.R.; Subrahmanyam, C.V. Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization. *Drug. Dev. Ind. Pharm.* **2013**, *40*(9), 1163-1172. DOI: 10.1590/s2175 97902022e191024
9. Suryawanshi, V.K.; Gidwani, B.; Verma, A.; Dubey, N.; Kaur, C.D. Formulation and evaluation of ramipril liquisolid compact using novel carrier. *Int. J. Pharm. Sci. Res.* **2019**, *10*(2), 917-25. DOI: 10.13040/IJPSR.0975-8232

10. Wankhede Navneet, B.; Walekar, S. S.; Sadgir, P.S.; Ahirrao, S.P. Lquisolid: A Novel Technique for Dissolution Enhancement of Poorly Water-Soluble Drugs. *Asian J. Pharm. Technol. Innov.* **2014**, *2(8)*, 77-90.
11. El-Hammadi, M.; Awad, N. Investigating the use of lquisolid compacts technique to minimize the influence of pH variations on loratadine release. *AAPS PharmSciTech.* **2012**, *13(1)*, 53-58. DOI: 10.1208/s12249-011-9719-6
12. Patel, G.K.; Patel, J. Formulation and evaluation of lquisolid compacts of rivaroxaban. *Int. J. Emerg. Technol. Innov. Res.* **2022**, *9(7)*, e152-e162
13. Spireas, S.; Bolton, M. Lquisolid systems and methods of preparing same. (Patent No: 6,423,339). United States Patent. 2002. Available at: <https://patents.google.com/patent/US6423339B1/en> (Accessed on 11 February 2025)
14. Sai, P.D.; Sivaiah, K.V.; Bonthagarala, B.; Rao, P.V. Review on lquisolid compact technology. *World. J. Pharm. Res.* **2014**, *4*, 293-306.
15. Nijhawan, M.; Godugu, M.; Saxena, T.; Farheen, T.; Dwivedi, K. Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties. *Braz. J. Pharm. Sci.* **2022**, *58*, Art. No: e191024. DOI: 10.1590/s2175 97902022e191024
16. Andrew E.C et al. Formulation and *in Vitro* Evaluation of Lquisolid Compact of Celecoxib. *Mathews J. Pharm. Sci.* **2024**, *8(2)*, Art. No: 31. DOI: 10.30654/MJPS.10031
17. Patel, U.B.; Modi, D.C.; Shah, D.P. Lquisolid compacts: A review. *Int. J. Adv. Pharm.* **2017**, *6(7)*, 110-3.
18. Madhavi Harika Srimathkandala, Sushma M, Madhu Babu Ananthula, Vasudha Bakshi. Formulation and evaluation of Loperamide Lquisolid compacts. *Int. J. Pharm.* **2016**, *6(2)*, 93-99.
- 19., Costa, P.; Sousa Lobo, J.M.. Modeling and comparison of dissolution profiles, *Eur. J. Pharm. Sci.* **2001**, *13(2)*, 123-133. DOI: 10.1016/s0928-0987(01)00095-1
20. Kassaye, L.; Genete, G. Evaluation and comparison of *in-vitro* dissolution profiles for different brands of amoxicillin capsules. *Afr. Health. Sci.* **2013**, *13(2)*, 369-375. DOI: 10.4314/ahs.v13i2.25